TCR-Mimic Antibodies & CARs
Cancer, Viral infections
Pre-clinicalActive
Key Facts
About SyntIV
SyntIV is a private, early-stage biotech firm applying synthetic biology to create next-generation immunotherapies and biologics. Its technology platform centers on engineering antibodies with extended antigen recognition sites to target occluded viral and cancer proteins, and on developing T cell receptor-mimicking antibodies for cell therapy applications. The company is partially owned by and holds a license from the University of Minnesota, building on foundational research from the Herschhorn Lab. SyntIV appears to be in a pre-revenue, pre-clinical stage, generating early validation through scientific publications while also offering a catalog of research proteins and DNA tools.
View full company profile